• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

积极治疗的骨肉瘤的肿瘤大小与预后

Tumor size and prognosis in aggressively treated osteosarcoma.

作者信息

Bieling P, Rehan N, Winkler P, Helmke K, Maas R, Fuchs N, Bielack S, Heise U, Jurgens H, Treuner J, Romanowski R, Exner U, Kotz R, Winkler K

机构信息

Department of Pediatric Oncology, University of Hamburg, Germany.

出版信息

J Clin Oncol. 1996 Mar;14(3):848-58. doi: 10.1200/JCO.1996.14.3.848.

DOI:10.1200/JCO.1996.14.3.848
PMID:8622033
Abstract

PURPOSE

The aim of this retrospective analysis was to investigate the prognostic significance and optimal measures of tumor size in osteosarcoma treated with intensive neoadjuvant chemotherapy.

PATIENTS AND METHODS

Initial anterior-posterior (AP) and lateral x-ray films of 128 patients treated within the trials Cooperative Osteosarcoma Study (COSS)-80, -82, and -86, were evaluated for the following three tumor diameters: length, width, and depth. Metastasis-free survival (MFS) analyses were performed in univariate and multivariate models with one, two, and three dimensions of the tumor as absolute or relative measures (tumor length, referred to bone length, plane and volume to body-surface area).

RESULTS

Univariate analyses of MFS showed a high prognostic significance of all absolute measures. Relative measures, at best, showed a comparable predictive value. Cox regression analysis indicated the high prognostic significance of absolute tumor volume (ATV; P < .0001) and histologic response (P < .0001). None of 19 patients with an ATV < or = 70 cm3 and only four of 53 with an ATV < or = 150 cm3 relapsed, while in patients with an ATV more than 150 cm3, the relapse rate remained 40% to 60%, irrespective of further increase in volume.

CONCLUSION

Initial tumor size is an important and easily obtainable prognostic factor in osteosarcoma and may serve as a basis for risk-adapted therapy. It is best represented by the absolute three-dimensional measure ATV. There is a cut-off point regarding the incidence of metastases at a tumor volume of approximately 150 cm3 as calculated from two-plane x-ray films.

摘要

目的

本回顾性分析旨在研究骨肉瘤患者接受强化新辅助化疗时肿瘤大小的预后意义及最佳测量方法。

患者与方法

对在骨肉瘤协作研究(COSS)-80、-82和-86试验中接受治疗的128例患者的初始前后位(AP)和侧位X线片进行评估,测量以下三个肿瘤直径:长度、宽度和深度。在单变量和多变量模型中进行无转移生存期(MFS)分析,将肿瘤的一维、二维和三维作为绝对或相对测量指标(肿瘤长度相对于骨长度、平面和体积相对于体表面积)。

结果

MFS的单变量分析显示所有绝对测量指标均具有较高的预后意义。相对测量指标充其量显示出相当的预测价值。Cox回归分析表明绝对肿瘤体积(ATV;P <.0001)和组织学反应(P <.0001)具有较高的预后意义。19例ATV≤70 cm³的患者均未复发,53例ATV≤150 cm³的患者中只有4例复发,而ATV超过150 cm³的患者,无论体积进一步增加,复发率仍为40%至60%。

结论

初始肿瘤大小是骨肉瘤中一个重要且易于获得的预后因素,可作为风险适应性治疗的基础。它最好由绝对三维测量指标ATV来表示。根据双平面X线片计算,肿瘤体积约150 cm³时转移发生率存在一个临界点。

相似文献

1
Tumor size and prognosis in aggressively treated osteosarcoma.积极治疗的骨肉瘤的肿瘤大小与预后
J Clin Oncol. 1996 Mar;14(3):848-58. doi: 10.1200/JCO.1996.14.3.848.
2
[The prognostic significance of tumor volume in osteosarcoma with neoadjuvant chemotherapy].[新辅助化疗后骨肉瘤肿瘤体积的预后意义]
Klin Padiatr. 1993 Jul-Aug;205(4):200-9. doi: 10.1055/s-2007-1025228.
3
Relative tumor burden predicts metastasis-free survival in pediatric osteosarcoma.相对肿瘤负荷可预测儿童骨肉瘤的无转移生存期。
Pediatr Blood Cancer. 2008 Feb;50(2):195-200. doi: 10.1002/pbc.21446.
4
Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols.原发性转移性骨肉瘤:接受新辅助骨肉瘤协作研究组方案治疗患者的表现及预后
J Clin Oncol. 2003 May 15;21(10):2011-8. doi: 10.1200/JCO.2003.08.132.
5
[Neoadjuvant therapy for localized osteosarcoma of extremities. Results from the Cooperative osteosarcoma study group COSS of 925 patients].[肢体局限性骨肉瘤的新辅助治疗。来自骨肉瘤协作研究组COSS的925例患者的结果]
Klin Padiatr. 1999 Jul-Aug;211(4):260-70. doi: 10.1055/s-2008-1043798.
6
Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution.新辅助化疗治疗肢体骨肉瘤的预后因素:单机构789例患者的15年经验
Cancer. 2006 Mar 1;106(5):1154-61. doi: 10.1002/cncr.21724.
7
Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremities.P-糖蛋白和临床病理因素在肢体高级别骨肉瘤新治疗策略中的价值
J Clin Oncol. 2003 Feb 1;21(3):536-42. doi: 10.1200/JCO.2003.03.144.
8
Telangiectatic osteosarcoma of the extremity: neoadjuvant chemotherapy in 24 cases.肢体毛细血管扩张性骨肉瘤:24例新辅助化疗
Acta Orthop Scand. 2001 Apr;72(2):167-72. doi: 10.1080/000164701317323426.
9
Examination of the cutoff value of postchemotherapy increase in tumor volume as a predictor of subsequent oncologic events in stage IIB osteosarcoma.化疗后肿瘤体积增加的截断值评估对 IIB 期骨肉瘤后续肿瘤事件的预测价值。
J Surg Oncol. 2014 Mar;109(3):275-9. doi: 10.1002/jso.23496. Epub 2013 Nov 14.
10
Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS).综合治疗后骨肉瘤复发:对骨肉瘤协作研究组(COSS)中未经挑选患者的分析。
J Clin Oncol. 2005 Jan 20;23(3):559-68. doi: 10.1200/JCO.2005.04.063.

引用本文的文献

1
Periprosthetic seromas and a third space effect after high-dose methotrexate.高剂量甲氨蝶呤治疗后的假体周围血清肿和第三间隙效应
Wien Klin Wochenschr. 2024 Nov 11. doi: 10.1007/s00508-024-02467-6.
2
Characteristics and prognostic factors of adult patients with osteosarcoma from the SEER database.SEER 数据库中骨肿瘤患者的特征和预后因素。
Medicine (Baltimore). 2023 Sep 15;102(37):e33653. doi: 10.1097/MD.0000000000033653.
3
Comprehensive analysis of copper-metabolism-related genes about prognosis and immune microenvironment in osteosarcoma.
骨肉瘤中铜代谢相关基因与预后和免疫微环境的综合分析。
Sci Rep. 2023 Sep 12;13(1):15059. doi: 10.1038/s41598-023-42053-w.
4
Clinical Targeted Next-Generation Panel Sequencing Reveals Amplification Is a Poor Prognostic Factor in Osteosarcoma.临床靶向下一代基因测序panel 揭示骨肉瘤中扩增是一个不良预后因素。
JCO Precis Oncol. 2023 Mar;7:e2200334. doi: 10.1200/PO.22.00334.
5
Establishment, Maintenance, and Performance of the Cooperative Osteosarcoma Study Group (COSS).骨肉瘤协作研究组(COSS)的组建、维持及成效
Cancers (Basel). 2023 Feb 28;15(5):1520. doi: 10.3390/cancers15051520.
6
Analysis of prognostic factors and histopathological response to neoadjuvant chemotherapy in osteosarcoma.骨肉瘤新辅助化疗的预后因素及组织病理学反应分析。
Jt Dis Relat Surg. 2023;34(1):196-206. doi: 10.52312/jdrs.2023.902. Epub 2023 Jan 14.
7
A Nomogram for Predicting Cancer-Specific Survival of Osteosarcoma and Ewing's Sarcoma in Children: A SEER Database Analysis.基于 SEER 数据库的儿童骨肉瘤和尤文肉瘤特异性生存预测列线图分析
Front Public Health. 2022 Feb 1;10:837506. doi: 10.3389/fpubh.2022.837506. eCollection 2022.
8
When SUV Matters: FDG PET/CT at Baseline Correlates with Survival in Soft Tissue and Ewing Sarcoma.当SUV起关键作用时:基线FDG PET/CT与软组织肉瘤和尤因肉瘤的生存率相关。
Life (Basel). 2021 Aug 24;11(9):869. doi: 10.3390/life11090869.
9
Clinical features and outcomes of metastatic bone tumors of the pelvis.骨盆转移性骨肿瘤的临床特征和预后。
J Int Med Res. 2021 Jun;49(6):3000605211013152. doi: 10.1177/03000605211013152.
10
MRI-based radiomics signature for pretreatment prediction of pathological response to neoadjuvant chemotherapy in osteosarcoma: a multicenter study.基于 MRI 的放射组学特征预测骨肉瘤新辅助化疗的病理反应:一项多中心研究。
Eur Radiol. 2021 Oct;31(10):7913-7924. doi: 10.1007/s00330-021-07748-6. Epub 2021 Mar 30.